BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18314442)

  • 1. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
    Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
    Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
    Rassenti LZ; Jain S; Keating MJ; Wierda WG; Grever MR; Byrd JC; Kay NE; Brown JR; Gribben JG; Neuberg DS; He F; Greaves AW; Rai KR; Kipps TJ
    Blood; 2008 Sep; 112(5):1923-30. PubMed ID: 18577710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
    Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
    Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
    Morilla A; Gonzalez de Castro D; Del Giudice I; Osuji N; Else M; Morilla R; Brito Babapulle V; Rudenko H; Matutes E; Dearden C; Catovsky D; Morgan GJ
    Leuk Lymphoma; 2008 Nov; 49(11):2108-15. PubMed ID: 19021053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
    Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
    Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.
    Nichols EM; Jones R; Watson R; Pepper CJ; Fegan C; Marchbank KJ
    Oncotarget; 2015 Oct; 6(32):32669-80. PubMed ID: 26452134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
    Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
    J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.
    Xu W; Cao X; Miao KR; Qiao C; Wu YJ; Liu Q; Fan L; Li JY
    Int J Hematol; 2009 Sep; 90(2):205-211. PubMed ID: 19629630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status.
    Hüttmann A; Klein-Hitpass L; Thomale J; Deenen R; Carpinteiro A; Nückel H; Ebeling P; Führer A; Edelmann J; Sellmann L; Dührsen U; Dürig J
    Leukemia; 2006 Oct; 20(10):1774-82. PubMed ID: 16932341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
    Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
    Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
    Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
    Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
    Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia.
    Kazemi T; Asgarian-Omran H; Hojjat-Farsangi M; Shabani M; Memarian A; Sharifian RA; Razavi SM; Jeddi-Tehrani M; Rabbani H; Shokri F
    Int J Cancer; 2008 Nov; 123(9):2113-9. PubMed ID: 18704934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia.
    Stamatopoulos B; Meuleman N; Haibe-Kains B; Duvillier H; Massy M; Martiat P; Bron D; Lagneaux L
    Clin Chem; 2007 Oct; 53(10):1757-66. PubMed ID: 17702857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
    Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
    Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
    Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
    Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.
    Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
    Cancer Sci; 2009 Dec; 100(12):2346-53. PubMed ID: 19824994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status.
    Baptista MJ; Muntañola A; Calpe E; Abrisqueta P; Salamero O; Fernández E; Codony C; Giné E; Kalko SG; Crespo M; Bosch F
    Clin Cancer Res; 2012 Nov; 18(21):5924-33. PubMed ID: 22966019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
    Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
    Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia.
    Chen L; Zhang Y; Zheng W; Wu Y; Qiao C; Fan L; Xu W; Li J
    Leuk Res; 2008 Oct; 32(10):1491-8. PubMed ID: 18359082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.